BP1210 / BrightPath Biotherap - LARVOL DELTA

Results of preclinical research into anti-TIM-3 biparatopic antibody (BP1210) targeting hematological cancers to be presented at the Immunology Society 2024 [Google translation] (Nikkei) - "The presented data is related to the efficacy and pharmacology of acute myeloid leukemia (AML) obtained through a joint research project with the National Cancer Center, and is the first case of BP1210 being used in the treatment of hematological cancer (AML)...The main announcements are as follows: BP1210 suppressed the exhaustion of T cells, which play a central role in anti-tumor immunity, and enhanced anti-tumor immune activity; In addition, BP1210 also bound to TIM-3 expressed in LSCs derived from AML patients, inhibited LSC self-renewal mediated by TIM-3/Gal-9 signaling, and strongly promoted the internalization of TIM-3 on LSCs; Because BP1210 has a dual mechanism of action, enhancing anti-tumor immunity such as T cells and inhibiting LSC self-renewal, it has been found to be a promising candidate for the treatment of AML."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology